- Home
- About
- Find staff
- Tzu-Po Chuang
Tzu-Po Chuang
Researcher
Department of Medical Biochemistry and Cell biology-
Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA
Analysis
Torben Ek, Raghda Ragab Mohamed Hassan Ahmed Ibrahim, Hartmut Vogt, Kleopatra Georgantzi, Catarina Trager, Jennie Gaarder, Anna Djos, Ida Rahmqvist, Elisabeth Mellström, Fani Pujol-Calderón, Christoffer Vannas, Lina Hansson, Henrik Fagman, Diana Treis, Susanne Fransson, Tobias Österlund, Tzu-Po Chuang, Bronte Manouk Verhoeven, Anders Ståhlberg, Ruth H. Palmer, Bengt Hallberg, Tommy Martinsson, Per Kogner, Martin Dalin
Cancer Research Communications - 2024 -
Anaplastic Lymphoma Kinase signaling stabilizes SLC3A2 expression via MARCH11 to promote neuroblastoma cell
growth
Wei-Yun Lai, Tzu-Po Chuang, Marcus Borenäs, Dan E. Lind, Bengt Hallberg, Ruth H. Palmer
CELL DEATH AND DIFFERENTIATION - 2024 -
ALK F1174S mutation impairs ALK kinase activity in EML4-ALK variant 1 and sensitizes EML4-ALK variant 3 to
crizotinib
Jikui Guan, Tzu-Po Chuang, Anders Vikstrom, Ruth H. Palmer, Bengt Hallberg
FRONTIERS IN ONCOLOGY - 2024 -
ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4
expression
Tzu-Po Chuang, Wei-Yun Lai, Jonatan L. Gabre, Dan E. Lind, Ganesh Umapathy, Abdulmalik Bokhari, Bengt Bergman, Linnea Kristenson, Fredrik Bergh Thorén, Anh Le, Robert C. Doebele, Jimmy Van den Eynden, Ruth H. Palmer, Bengt Hallberg
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA - 2023 -
Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in
NSCLC
Abdulmalik Bokhari, Wei-Yun Lai, A. T. Le, Jonatan L. Gabre, Tzu-Po Chuang, Susanne Fransson, B. Bergman, Anna Djos, N. Chen, Tommy Martinsson, J. Van den Eynden, R. C. Doebele, Ruth H. Palmer, Bengt Hallberg, Ganesh Umapathy
Lung Cancer - 2022 -
ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK
mutation.
Marcus Borenäs, Ganesh Umapathy, Wei-Yun Lai, Dan E. Lind, Barbara Witek, Jikui Guan, Patricia Mendoza-García, Tafheem Masudi, Arne Claeys, Tzu-Po Chuang, Abeer El Wakil, Badrul Arefin, Susanne Fransson, Jan Koster, Mathias Johansson, Jennie Gaarder, Jimmy Van den Eynden, Bengt Hallberg, Ruth H. Palmer
The EMBO journal - 2021